Cristina Campos is well known on the Portuguese pharmaceutical circuit, directing the affiliate of market leader, Novartis, and holding a position as vice-president at APIFARMA, the Portuguese Pharmaceutical Association. In her second meeting with PharmaBoardroom, Campos discusses the Portuguese ‘talent machine’, an exciting new portfolio with incredibly strong launches on the way, the company’s sustained commitment to innovation and the clinical trials landscape.
A new global CEO since February 2018, welcome develops in improving market access in Portugal, and a positive economic climate in Portugal. What are your current priorities for the Novartis affiliate in this encouraging environment?
We will fuel innovation in the next three years, as we expect to bring 11 new treatments to Portugal in our Pharma portfolio and several new molecules and indications in hematology and solid tumors
